IPO Boutique Research, Color & More Information for Subscribers
This content is restricted to IPO Boutique Subscribers Username or Email Password Remember me Lost your password? Become a Subscriber Disclaimer IPO Boutique aggregates information on public companies and private companies, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry[…]
This content is restricted to IPO Boutique Subscribers Username or Email Password Remember me Lost your password? Become a Subscriber Disclaimer IPO Boutique aggregates information on public companies and private companies, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry[…]
This content is restricted to IPO Boutique Subscribers Username or Email Password Remember me Lost your password? Become a Subscriber Disclaimer IPO Boutique aggregates information on public companies and private companies, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry[…]
This content is restricted to IPO Boutique Subscribers Username or Email Password Remember me Lost your password? Become a Subscriber Disclaimer IPO Boutique aggregates information on public companies and private companies, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry[…]
Company: BioXcel Therapeutics, Inc. Symbol: BTAI Description: They are a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology. Trade Date: 3/8 Shares: 5 million Price Range: $11.00-$13.00 Underwriter(s): Barclays, UBS Investment Bank, BMO Capital Markets Co-Manager(s): Canaccord[…]